Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564599 | 0.93 | HRH3 (0.36) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL356238 | 0.86 | KMT2A (0.38) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL1097457 | 0.79 | KMT2A (0.37) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL806010 | 0.77 | GNAI3 (0.41) | KMT2AMEN1HPGDNPC1ALDH1A1 | |
| SCHEMBL1097459 | 0.77 | KMT2A (0.36) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL4057851 | 0.77 | KMT2A (0.40) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL1098265 | 0.77 | KEAP1 (0.50) | KMT2AMEN1 | |
| SCHEMBL17556136 | 0.77 | KMT2A (0.36) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL1098264 | 0.77 | KMT2A (0.36) | KMT2AMEN1HPGDCYP1A2CYP2C19 | |
| SCHEMBL27784922 | 0.77 | HRH3 (0.32) | HRH3PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| WO-2010072823-A1 | PYRAZOLE[1,5a]PYRIDINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| WO-2010034740-A1 | (R)-3-(N,N-DIMETHYLAMINO)PYRROLIDINE DERIVATIVES | PALAU PHARMA, S.A. (ES) | 2010-04-01 | — | — | WO | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| EP-2118105-A1 | PURINE DERIVATIVES | Palau Pharma, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008090181-A1 | PURINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2008-07-31 | — | — | WO | disclosed |
| US-5585518-A | USEFUL INTERMEDIATES FOR THE SYNTHESIS OF METAL COMPLEX DYES, ESPECIALLY OF REACTIVE DYES BASED ON FORMAZANS | BASF AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | KMT2A 2029/4885MEN1 3780/4885HPGD 2187/4885 |
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | KMT2A 2127/4885MEN1 3520/4885HPGD 1230/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | KMT2A 2029/4885MEN1 3780/4885HPGD 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.